Status:

COMPLETED

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

Lead Sponsor:

Pfizer

Conditions:

Arthritis, Rheumatoid

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy ...

Eligibility Criteria

Inclusion

  • A diagnosis of severe rheumatoid arthritis (RA) for at least 6 months
  • The Rheumatoid Arthritis must have been treated with a stable regimen including a non-steroidal anti-inflammatory drug (NSAID), as well as methotrexate for at least 12 weeks -OR- an NSAID (for at least 12 weeks plus a tumor necrosis factor inhibitor (i.e., adalimumab \[Humira®\] for a minimum of 5 doses on a regular schedule, etanercept \[Enbrel®\] for 6 weeks, infliximab (Remicade®) for 3 doses and currently on a stable regimen of infusions not more than every 8 weeks)

Exclusion

  • A diagnosis of any other inflammatory arthritis or a secondary, noninflammatory type of arthritis (eg, osteoarthritis (OA) or fibromyalgia) that, in the investigator's opinion, was symptomatic enough to interfere with the evaluation of the effect of valdecoxib on the patient's primary diagnosis of Rheumatoid Arthritis were excluded from the study

Key Trial Info

Start Date :

February 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2005

Estimated Enrollment :

489 Patients enrolled

Trial Details

Trial ID

NCT00650455

Start Date

February 1 2003

End Date

January 1 2005

Last Update

July 21 2008

Active Locations (55)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (55 locations)

1

Pfizer Investigational Site

Birmingham, Alabama, United States, 35249-7201

2

Pfizer Investigational Site

Huntsville, Alabama, United States, 35801

3

Pfizer Investigational Site

Glendale, Arizona, United States, 85304

4

Pfizer Investigational Site

Glendale, Arizona, United States, 85308